Pharmather Inc (CSE: PHRM) this morning announced that it has amended its sponsored research agreement with that of the University Health Network. The revised agreement, which was originally just focused on the development of panaceAI, will now also include the development of a digital therapeutics platform to combine with potential psychedelic therapies.
The digital therapeutics program, which will be focused on continuously documenting patients biology and symptoms, will enable personalized medication regiments based on the information gathered on the individual as well as through big data. More specifically, the platform will be designed to integrate self monitoring applications and machine learning to monitor responses and benefits of the psychedelic compounds used to treat neurological disorders.
The digital therapeutics platform is to be developed by the Diamandis Lab, led by Dr Phedias Diamandis, whom is the principal investigator that is also advancing the firms work with panaceAI. PanacaAI is currently focused on merging big data with artificial intelligence to accelerate the process of drug discovery.
“We are excited to evolve our relationship with PharmaTher for the development and commercialization of a digital therapeutics solution for psychedelic medicines in the treatment of neurological disorders. My lab has been focused on developing artificial intelligence and machine learning tools directed with the goal of leveraging innovation in technology and digital solutions to address unmet medical needs. The amount of data and feedback you can collect and provide with digital technologies is unprecedented.”
Dr. Diamandis
The amended arrangement will see a dedicated team focused on developing this digital therapeutic platform for Pharmather. Financial terms of the arrangement were not released.
Pharmather Inc last traded at $0.23 on the CSE.
FULL DISCLOSURE: Pharmather is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Pharmather on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
